Developing Therapies Against Novel Cancer Targets
Our Antibody Drug Conjugates (ADCs) may serve as a highly effective treatment alternative to traditional chemotherapies.
Developing Therapies Against Novel Cancer Targets
Our Antibody Drug Conjugates (ADCs) may serve as a highly effective treatment alternative to traditional chemotherapies.
The MBrace Pipeline
We are using our proprietary discovery technology to build a pipeline of first-in-class ADCs targeting novel proteins.
- Discovery
- IND-Enabling
- Phase 1
- Phase 2
- Phase 3
- Dis
- IND-E
- P1
- P2
- P3
This ADC program targets solid tumors and hematologic cancers and is in initial stages of IND-Enabling studies.
Details are forthcoming.
For more information about MBrace’s products or programs please contact us at:
Accelerating antibody and drug target selection
Learn about our SPARTA technology, a unique in vivo antibody selection and target discovery process that is advancing ADC development.
Understanding antibody-drug conjugates
Accelerating antibody and drug target selection
Learn about our SPARTA technology, a unique in vivo antibody selection and target discovery process that is advancing ADC development.
